Using Bovine Growth Factor Gel for Sensitive Skin Treatment
The Application of Bovine Basic Fibroblast Growth Factor Gel in the Treatment of Sensitive Skin
This study is testing if a special gel made from a growth factor can help people with sensitive skin feel better by reducing redness.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 28 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Shanghai Dermatology Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT06516939 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of Bovine Basic Fibroblast Growth Factor Gel in treating individuals with sensitive skin characterized by persistent erythema. Participants must meet specific criteria, including a lactate irritation test score of 2-3 and a strict regimen of physical sunscreen during the study. The trial excludes individuals with certain health conditions and those who have used specific skin treatments recently. The goal is to assess how well this gel can alleviate symptoms associated with sensitive skin.
Who should consider this trial
Good fit: Ideal candidates are adults with sensitive skin diagnosed with persistent erythema and specific irritation test scores.
Not a fit: Patients with serious underlying health conditions, recent use of certain medications, or acute dermatitis may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide significant relief for patients suffering from sensitive skin conditions.
How similar studies have performed: There is limited information on similar studies, making this approach relatively novel in the context of sensitive skin treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Sensitive skin with a diagnosis of persistent erythema and a lactate irritation test score of 2-3 2. No related skin care products including bovine alkaline fibroblast growth factor were used within 1 month before participating in the experiment, and photoelectric treatment measures were not carried out 3. Physical sunscreen should be strict during enrollment Exclusion Criteria: 1. Children 2. Have serious heart, liver, kidney, and blood system diseases, and severe immunocompromise 3. Patients with mental illness or cancer 4. Those who have received glucocorticoids, calcineurin inhibitors, topical small molecule drugs, antibiotics or tretinoin within 3 months 5. Those who are allergic to basic fibroblast growth factor gel and its components 6. Acute dermatitis of the face and perifolliculitis
Where this trial is running
Shanghai
- Shanghai Skin Disease Hospital — Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Haiyan Zhang, MD PhD
- Email: zhanghaiyan10842@163.com
- Phone: 18017336573
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.